The company has completed its submission to WHO of all the modules required for the regulatory evaluation of its vaccine candidate, which is manufactured in partnership with the Serum Institute of India. Novavax said it will make further submissions to enable vaccine supply from additional manufacturing sites.

The company said it recently received authorization for its vaccine in Indonesia. It has submitted regulatory filings in the U.K., Australia, New Zealand, and Canada. Novavax said that it has also submitted data and modules in the European Union to support final regulatory review. Novavax expects to submit the complete package to the U.S. Food and Drug Administration by the end of the year.

Novavax submits COVID vaccine candidate to TGA
Novavax completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate in Australia.

Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...

Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing...

Novavax posts positive preclinical results for flu/COVID-19 vaccine
Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.

Novavax COVID-19 vaccine to be included in combo vaccine study
Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The...